文献速递肿瘤 PET/CT

基于FDG PET的影像组学模型预测非小细胞肺癌隐匿性淋巴结转移的开发与外部验证

Development and external validation of a FDG PET-based radiomics model predicting occult lymph node metastasis in non-small cell lung cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-01-16

本研究开发并外部验证了基于治疗前FDG PET的影像组学模型(ModelPET)及联合临床特征的模型(ModelCombined),用于预测局限性非小细胞肺癌(NSCLC)的隐匿性淋巴结转移(OLNM)。模型在训练队列中表现优异,但在外部验证队列中判别能力下降;ModelPET预测的OLNM风险与接受SBRT患者的区域无复发生存(RRFS)显著相关(HR 1.60,95%CI 1.03-2.48,p=0.04),而ModelCombined与生存结局无关。

要点

  • ModelPET在训练队列AUC为0.92,外部验证队列AUC为0.73,判别能力有所下降。
  • ModelCombined在训练队列AUC为0.99,外部验证队列AUC为0.67,Bacc仅51.7%。
  • 在SBRT队列中,ModelPET预测的OLNM风险与更差RRFS显著相关(HR 1.60,p=0.04)。

核心结论

  • 基于FDG PET的影像组学模型可用于预测局限性NSCLC的OLNM,并在多个回顾性独立队列中进行了验证。
  • ModelPET预测的OLNM风险与接受SBRT患者的区域无复发生存显著相关,而ModelCombined与生存结局无关。
  • 该模型需经前瞻性评估后,方可用于优化临床决策。

研究设计与样本

  • 回顾性单中心队列(Cohort A)用于开发ModelPET和ModelCombined,患者为接受手术的局限性NSCLC。
  • 外部验证队列(Cohort B)为公开的Radiogenomics队列,包含112例接受手术的局限性NSCLC患者。
  • 独立队列(Cohort C)包含488例接受确定性立体定向体部放疗(SBRT)的局限性NSCLC患者,以区域无复发生存(RRFS)作为OLNM的替代指标。
  • 影像组学特征从治疗前FDG PET中提取,采用多层感知机方法联合预测OLNM。

主要发现

  • 在训练队列中,ModelPET和ModelCombined的AUC分别为0.92和0.99,平衡准确率(Bacc)分别为80.0%和85.3%。
  • 在Cohort B中,ModelPET和ModelCombined的AUC分别为0.73和0.67,Bacc分别为71.2%和51.7%。
  • 在Cohort C中,基于ModelPET预测的OLNM风险与更差的RRFS显著相关(HR 1.60,95%CI 1.03-2.48,p=0.04)。
  • ModelCombined与生存 outcomes 无关(p > 0.05)。

临床怎么用

  • 对于局限性NSCLC患者,治疗前FDG PET影像组学模型(ModelPET)可辅助预测OLNM风险。
  • ModelPET预测的高OLNM风险与SBRT后区域复发风险增加相关,或可帮助筛选需更积极区域处理的患者。
  • 目前模型尚未进入临床常规,需前瞻性研究进一步验证后方可指导临床决策。

局限性

  • 研究为回顾性设计,结论需前瞻性评估确认。
  • 外部验证队列中模型判别能力较训练队列下降,ModelCombined的Bacc仅51.7%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE(S): Accurate detection of occult lymph node metastasis (OLNM) in patients with localized non-small cell lung cancer (NSCLC) remains a clinical challenge. This study aimed to develop and validate a radiomics-based predictive model for OLNM. MATERIALS/METHODS: A radiomics model (ModelPET) and a model (ModelCombined) combining radiomics and clinical features were developed using a retrospective monocentric cohort of localized NSCLC patients treated with surgery (Cohort A) and tested on an external cohort (Cohort B) of 112 localized NSCLC patients also treated with surgery (publicly available Radiogenomics cohort). The model was further assessed in an independent cohort of 488 patients with localized NSCLC who underwent definitive stereotactic body radiotherapy (SBRT) (Cohort C) using regional relapse free survival (RRFS) as a surrogate for OLNM. Radiomic features were extracted from pre-treatment FDG PET and combined to predict OLNM using a multilayer perceptron approach. RESULTS: In the training cohort, the ModelPET and ModelCombined achieved AUCs of 0.92/0.99 and balanced accuracies (Bacc) of 80.0%/85.3%, respectively. In the Cohort B, the ModelPET and ModelCombined resulted in AUCs of 0.73/0.67 and Baccs of 71.2%/51.7%, respectively. In the Cohort C, the predicted OLNM risk based on ModelPET was significantly associated with worse RFFS (HR 1.60 95% CI 1.03-2.48, p = 0.04). The ModelCombined was not associated with survival outcomes (p > 0.05). CONCLUSION: This study presents a radiomics-based predictive model for OLNM in localized NSCLC, validated across several retrospective independent cohorts. Subject to a prospective evaluation, the model could be used to refine clinical decision-making.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bourbonne V, Lovinfosse P, Geier M, et al. Development and external validation of a FDG PET-based radiomics model predicting occult lymph node metastasis in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2026. PMID: 41543547. doi:10.1007/s00259-025-07740-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。